Identification of the molecular subtype and prognostic characteristics of lung adenocarcinoma based on CD8 + T cell-related gene signature
Cancer Biomarkers · 2024
DOI: 10.1177/18758592241296764 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biomarkers, 2024. Verfasst von Keke Tang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, CD8-Positive T-Lymphocytes, Immunotherapy. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Zhejiang Medical Health Science and Technology Project.
Abstract (Originalsprache)
Background
Lung adenocarcinoma (LUAD) stands as a major respiratory malignancy with high mortality. With the advent of immunotherapy, new therapeutic avenues have emerged in cancer treatment.
Objective
Our focus aimed at developing a CD8 + T cell-based immune gene prognostic model (CDIGPM) for LUAD, shedding light on the immunological aspects and the potential advantages of immunotherapy in distinct CDIGPM-defined LUAD categories.
Methods
Data from LUAD patients were extracted from the TCGA and GEO databases (GSE11969). The differentially expressed genes (DEGs) were intersected with immune genes from ImmPort and InnateDB, yielding 89 significant immune genes related to CD8 + T cells (CDIGs). Univariate Cox regression and LASSO regression analyses were performed on 10 hub CDIGs (ADM, CAV1, CTSL, HLA-DMB, HLA-DQA1, IGHM, PLSCR1, PTGDS, S100A16, and WFDC2). Furthermore, the immunological attributes and the immunotherapy efficacy in CDIGPM-defined categories were explored. Moreover, to support the findings of the bioinformatics analysis, fifteen LUAD patients’ tumor and adjacent tissues were collected for qRT-PCR detection of CDIGPM-related genes.
Results
Kaplan-Meier analysis revealed that the high-CDIGPM group exhibited significantly poorer overall survival (OS) trajectories, whereas the low-CDIGPM group showed more favorable OS trajectories, indicating a better prognosis. Age, tumor stage, and CDIGPM score were identified as independent prognostic factors. The high-CDIGPM group was enriched in pathways related to the cell cycle, focal adhesion, and cancer, while the low-CDIGPM group was associated with immune response-related pathways. The CDIGPM model effectively differentiated clinical subtypes in patients with LUAD. QRT-PCR detection of Clinical LUAD samples also validated the differentially expression of CDIGPM model related genes.
Conclusions
The study highlights the prognostic importance of CDIGs in LUAD using the CDIGPM model, linking age, stage and CDIGPM score to poor outcomes. The identified genes and pathways provide potential therapeutic targets, deepening our understanding of LUAD's molecular landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
- Clinical Lab, Zhejiang Provincial Tongde Hospital, Hangzhou, Zhejiang, China.
Förderung
- Zhejiang Medical Health Science and Technology Project
Zitieren
APA
Tang, K., Shen, J., Liu, D., Che, J., Mao, Q., Zhou, Y., & Ye, H. (2024). Identification of the molecular subtype and prognostic characteristics of lung adenocarcinoma based on CD8 + T cell-related gene signature. Cancer Biomarkers. https://doi.org/10.1177/18758592241296764
Vancouver
Tang K, Shen J, Liu D, Che J, Mao Q, Zhou Y, et al. Identification of the molecular subtype and prognostic characteristics of lung adenocarcinoma based on CD8 + T cell-related gene signature. Cancer Biomarkers. 2024. doi:10.1177/18758592241296764
BibTeX
@article{Tang2024,
author = {Tang, Keke and Shen, Ji and Liu, Dan and Che, Jia and Mao, Qifen and Zhou, Yixuan and Ye, Hainan},
title = {Identification of the molecular subtype and prognostic characteristics of lung adenocarcinoma based on CD8 + T cell-related gene signature},
journal = {Cancer Biomarkers},
year = {2024},
doi = {10.1177/18758592241296764}
}
EUVIMED